Abstract
Advances in immunosuppression, guided by invasive endomyocardial biopsy for the assessment of graft rejection, have ushered heart transplantation into the clinical arena by the demonstration of acceptable 1-year outcomes. Further decreases in the risk of malignancy and cardiac allograft vasculopathy that improve long-term outcomes, are, however, still desired. Attention has become directed towards the use of markers that can be detected noninvasively to provide insight into underlying molecular and cellular events associated with the immune response and graft function. Various candidate, protein-based markers have been identified: those of alloimmune activation; those of microvascular injury, such as cardiac-specific troponins; those of inflammation, including C-reactive protein; and surrogate markers of cardiac function, including natriuretic peptides such as brain natriuretic peptide. In the realm of genomics, it is becoming increasingly clear that a single molecular marker is unlikely to prove to be useful, but rather that multiple genes from a number of pathways are needed to capture biological complexity and overcome variability in the general population. Thus, the field of protein-based and gene-based biomarkers is advancing rapidly to define its place in clinical therapeutics and to guide immunosuppression according to molecular mechanisms of disease. We discuss here the main findings for the more-successful protein markers identified so far, and the genomic molecular approaches being used to improve heart transplant outcomes.
Key Points
-
Single-gene polymorphisms are helpful in understanding outcomes after heart transplantation but are not established as useful clinical monitoring tools
-
Peripheral blood mononuclear cell multigene-based molecular assays have shown the most promise for the discrimination of immunologic allograft quiescence and can anticipate future rejection
-
Protein-based biomarkers are less costly than gene-based biomarkers but more study is needed to guide their clinical use, although their negative predictive value seems most useful.
-
The protein-based biomarkers troponin (microvascular injury) C-reactive protein (inflammation) and brain natriuretic peptide (allograft wall stress and remodeling) correlate well with allograft failure and vasculopathy
-
The ideal noninvasive biomarker in heart transplantation will probably combine gene-based and protein-based approaches in a complementary manner rather than use these approaches in isolation
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mehra MR et al. (2002) Anything but a biopsy: noninvasive monitoring for cardiac allograft rejection. Curr Opin Cardiol 17: 131–136
Marboe CC et al. (2005) Nodular endocardial infiltrates (Quilty lesions) cause significant variability in diagnosis of ISHLT grade 2 and 3A rejection in cardiac allograft recipients. J Heart Lung Transplant 24 (Suppl): S219–226
Mehra MR (2005) The emergence of genomic and proteomic biomarkers in heart transplantation. J Heart Lung Transplant 24 (Suppl): S213–218
Awad MR et al. (2001) The effect of cytokine gene polymorphisms on pediatric heart allograft outcome. J Heart Lung Transplant 20: 625–630
Webber SA et al. (2002) Polymorphisms in cytokine genes do not predict progression to end-stage heart failure in children. Cardiol Young 12: 461–464
Abdallah AN et al. (1999) Analysis of the polymorphism of the tumour necrosis factor (TNF) gene and promoter and of circulating TNF-alpha levels in heart-transplant patients suffering or not suffering from severe rejection. Eur J Immunogenet 26: 249–255
Densem CG et al. (2001) Influence of tumor necrosis factor-alpha gene-308 polymorphism on the development of coronary vasculopathy after cardiac transplantation. J Heart Lung Transplant 20: 1265–1273
Borozdenkova S et al. (2001) Identification of ICAM1 polymorphism that is associated with protection from transplant associated vasculopathy after cardiac transplantation. Hum Immunol 62: 247–255
Pethig K et al. (2000) ACE-gene polymorphism is associated with the development of allograft vascular disease in heart transplant recipients. J Heart Lung Transplant 19: 1175–1182
Baan CC et al. (2000) Renal failure after clinical heart transplantation is associated with the TGF-β 1 codon 10 gene polymorphism. J Heart Lung Transplant 19: 866–872
Ojo AO et al. (2003) Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349: 931–940
Zheng H et al. (2003) Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 3: 477–483
Zheng HX et al. (2004) The impact of pharmacogenomic factors on steroid dependency in pediatric heart transplant patients using logistic regression analysis. Pediatr Transplant 8: 551–557
Holweg CT et al. (2004) Clinical impact of cytokine gene polymorphisms in heart and lung transplantation. J Heart Lung Transplant 23: 1017–1026
Christopher K et al. (2004) Modulation of gene expression by alloimmune networks following murine heart transplantation. Mol Genet Genomics 271: 687–696
Matsui Y et al. (2003) Identification of gene expression profile in tolerizing murine cardiac allograft by costimulatory blockade. Physiol Genomics 15: 199–208
DeFina R et al. (2003) Analysis of costimulation by 4-1BBL, CD40L, and B7 in graft rejection by gene expression profiles. J Mol Med 81: 655–663
Shulzhenko N et al. (2001) Intragraft activation of genes encoding cytotoxic T lymphocyte effector molecules precedes the histological evidence of rejection in human cardiac transplantation. Transplantation 72: 1705–1708
de Groot-Kruseman HA et al. (2003) Differential intragraft cytokine messenger RNA profiles during rejection and repair of clinical heart transplants. A longitudinal study. Transpl Int 16: 9–14
Fahmy NM et al. (2003) Chemokine and chemokine receptor gene expression indicates acute rejection of human cardiac transplants. Transplantation 75: 72–78
Horwitz PA et al. (2004) Detection of cardiac allograft rejection and response to immunosuppressive therapy with peripheral blood gene expression. Circulation 110: 3815–3821
Morgun A et al. (2003) Blood and intragraft CD27 gene expression in cardiac transplant recipients. Clin Immunol 107: 60–64
Schoels M et al. (2004) Detection of cardiac allograft rejection by real-time PCR analysis of circulating mononuclear cells. Clin Transplant 18: 513–517
Deng M et al. (2006) Non-invasive detection of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 6: 150–160
Starling R et al. (2005) The influence of corticosteroids on the alloimmune molecular signature for cardiac allograft rejection. J Heart Lung Transplant 24 (Suppl): S65–66
Re F et al. (1994) The type II “receptor” as a decoy target for interleukin 1 in polymorphonuclear leukocytes: characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor. J Exp Med 179: 739–743
Bernstein D et al. (2005) Gene expression profiling of cardiac allograft recipients with mild acute cellular rejection [abstract]. J Heart Lung Transplant 24 (Suppl): S65
Evans RW et al. (2005) The economic implications of noninvasive molecular testing for cardiac allograft rejection. Am J Transplant 5: 1553–1558
Borozdenkova S et al. (2004) Use of proteomics to discover novel markers of cardiac allograft rejection. J Proteome Res 3: 282–288
De Souza AI et al. (2005) Heat shock protein 27 is associated with freedom from graft vasculopathy after human cardiac transplantation. Circ Res 97: 192–198
Tambur AR et al. (2000) Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection. Transplantation 70: 1055–1059
Kobashigawa JA et al. (1996) Pretransplant panel reactive-antibody screens. Are they truly a marker for poor outcome after cardiac transplantation? Circulation 94 (Suppl): II294–II297
Taylor DO et al. (2000) Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. J Heart Lung Transplant 19: 518–521
Thompson JS et al. (2000) The influence of conventional and cross-reactive group HLA matching on cardiac transplant outcome: an analysis from the United Network of Organ Sharing Scientific Registry. Transplantation 69: 2178–2186
John R et al. (2000) Impact of current management practices on early and late death in more than 500 consecutive cardiac transplant recipients. Ann Surg 232: 302–311
Itescu S et al. (1998) An immunological algorithm to predict risk of high-grade rejection in cardiac transplant recipients. Lancet 352: 263–270
Mehra MR et al. (2004) The impact of mode of donor brain death on cardiac allograft vasculopathy: an intravascular ultrasound study. J Am Coll Cardiol 43: 806–810
Yamani MH et al. (2002) Myocardial ischemic-fibrotic injury after human heart transplantation is associated with increased progression of vasculopathy, decreased cellular rejection and poor long-term outcome. J Am Coll Cardiol 39: 970–977
Taegtmeyer AB et al. (2004) Reduced incidence of hypertension after heterotopic cardiac transplantation compared with orthotopic cardiac transplantation: evidence that excision of the native heart contributes to post-transplant hypertension. J Am Coll Cardiol 44: 1254–1260
Labarrere CA et al. (2000) Cardiac-specific troponin I levels and risk of coronary artery disease and graft failure following heart transplantation. JAMA 284: 457–464
Benza RL et al. (1998) Gene polymorphisms for plasminogen activator inhibitor-1/tissue plasminogen activator and development of allograft coronary artery disease. Circulation 98: 2248–2254
Labarrere CA et al. (1995) Vascular tissue plasminogen activator and the development of coronary artery disease in heart-transplant recipients. N Engl J Med 333: 1111–1116
Yamani MH et al. (2002) Acute vascular rejection is associated with up-regulation of vitronectin receptor (αvβ3), increased expression of tissue factor, and activation of the extracellular matrix metalloproteinase induction system. J Heart Lung Transplant 21: 983–989
Ventura HO and Mehra MR (2003) C-Reactive protein and cardiac allograft vasculopathy is inflammation the critical link? J Am Coll Cardiol 42: 483–485
Eisenberg MS et al. (2000) Elevated levels of plasma C-reactive protein are associated with decreased graft survival in cardiac transplant recipients. Circulation 102: 2100–2104
Pethig K et al. (2000) Systemic inflammatory response in cardiac allograft vasculopathy: high-sensitivity C-reactive protein is associated with progressive luminal obstruction. Circulation 102 (Suppl 3): III233–III236
Labarrere CA et al. (2002) C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study. Lancet 360: 1462–1467
Hognestad A et al. (2003) Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients. J Am Coll Cardiol 42: 477–482
Autieri MV et al. (2002) Allograft inflammatory factor-1 expression correlates with cardiac rejection and development of cardiac allograft vasculopathy. Circulation 106: 2218–2223
Mehra MR et al. (2004) Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation. Am J Cardiol 94: 454–458
Mehra MR et al. (2004) Molecular pathways of cardiac allograft dysfunction independent of acute cellular rejection [abstract]. J Am Coll Cardiol 43 (Suppl A): 1051–1127: 175A
Ogawa T et al. Neuroendocrine profiling of humans receiving cardiac allografts. J Heart Lung Transplant 24: 1046–1054
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Mandeep R Mehra has received research grants or consulting fees from Biosite Diagnostics and XDx Inc., makers of the brain natriuretic peptide assay and Allomap, respectively. Steve Rosenberg is currently employed by XDx Inc.
Rights and permissions
About this article
Cite this article
Mehra, M., Feller, E. & Rosenberg, S. The promise of protein-based and gene-based clinical markers in heart transplantation: from bench to bedside. Nat Rev Cardiol 3, 136–143 (2006). https://doi.org/10.1038/ncpcardio0457
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio0457